Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical...

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.

Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in...

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531...

Agilent Technologies has selected Turner Construction to build its previously announced new API plant in Frederick, Colorado, USA. The project is scheduled for completion...

British pharma GSK has entered into a four-year collaboration with US clinical-stage genetic medicines company Wave Life Sciences to advance oligonucleotide therapeutics...

Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.

Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.